Sana Biotechnology, Inc. (SANA): Cash & Equivalents
$71.87M
As of 2025-12-31
$57.07M
As of 2026-06-30
-25.9%
3-year compound annual growth
-10.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.87M | -43.7% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $127.57M | -4.5% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $133.52M | -24.5% | 2026-03-03, Balance as of period end |
| 2022-12-31 | $176.76M | -30.1% | 2025-03-17, Balance as of period end |
| 2021-12-31 | $253.03M | +102.7% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $124.81M | n/a | 2023-03-16, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $71.87M | -43.7% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $51.69M | -31.3% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $323.53M | +81.9% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $189.25M | -3.8% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $88.33M | +6.4% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $129.88M | -42.1% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $34.47M | -40.1% |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $396.49M | +383.8% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.96M | +51.4% |
Compare SANA, ALLO, SRRK, MAZE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗